Patents by Inventor Steven Libutti

Steven Libutti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENHANCING IMMUNE RESPONSES THROUGH TARGETED ANTIGEN EXPRESSION
    Publication number: 20230241203
    Abstract: The present disclosure includes an immunogenic composition comprising an effective amount of a therapeutic engineered phage and a pharmaceutically acceptable carrier. In certain aspects, the disclosure includes a method of stimulating an immune response in a subject comprising administering to the subject a composition comprising an effective amount of a therapeutic engineered phage. In certain aspects, the disclosure includes a method for treating, ameliorating, and/or preventing a coronavirus infection in a subject comprising administering a composition comprising an effective amount of a therapeutic engineered phage.
    Type: Application
    Filed: July 3, 2021
    Publication date: August 3, 2023
    Inventors: Renata Pasqualini, Wadih Arap, Steven Libutti, Christopher Markosian, Daniela Staquicini, Fenny Tang, Tracey Smith, Virginia Yao
  • Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
    Publication number: 20050175980
    Abstract: A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis.
    Type: Application
    Filed: April 9, 2003
    Publication date: August 11, 2005
    Applicant: Government of the United States of America, repres by the Secretary, Dept. of Health and Human Serv.
    Inventors: Steven Libutti, Mark Kayton
  • Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
    Publication number: 20050136006
    Abstract: A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis. Furthermore, such measurements of angiogenic or antiangiogenic activity may be monitored in an animal or patient afflicted with a disease.
    Type: Application
    Filed: December 16, 2004
    Publication date: June 23, 2005
    Applicant: Government of the U.S.A.,represented by the Secretary, Department of Health & Human Services
    Inventors: Steven Libutti, Mark Kayton